I think that's one of the really tough questions here. The vaccines that have really succeeded are these mRNA vaccines. The world is really not so much in a race for vaccines at this point; we're in a race for lipid nanoparticles, which were developed by a Vancouver firm but are licensed to many people around the world. People are scaling up in the United States and Europe and elsewhere. That's one of the big blocs—there are other blocs as well—that are really scaling up fast. Not only would you have to get people up to speed in producing more vaccines, vaccine technology and the transfer of technology, but you also have to somehow scale up that whole process of creating the lipid nanoparticles.
It is really hard. One of the reasons we're fighting about the export controls from Europe and wherever else is these very shortages. It's a very tough Rubik's cube to solve.